主题：【悬赏帖】求助英文文献4篇

【序号】：1
【作者】：Mazzei T1, Mini E, Eandi M, Reali EF, Fioretto L, Bartoletti R, Rizzo M, Calabrò G, Periti P.
【题名】：Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced
prostatic cancer: a dose-response evaluation.
【期刊】：Drugs Exp Clin Res. 1
【年、卷、期、起止页码】:1989;15(8):373-87.
【全文链接】：https://www.ncbi.nlm.nih.gov/pubmed/2513176
【序号】：2
【作者】：Niijima T1, Aso Y, Akaza H, Fujita K, Fuse H, Hosaka M, Isurugi K, Kamidono S, Katayama T,
Kawabe K, et al.
【题名】：[Clinical phase I and phase II study on a sustained release formulation of leuprorelin acetate
(TAP-144-SR), an LH-RH agonist, in patients with prostatic carcinoma. Collaborative++ Studies on
Prostatic Carcinoma by the Study Group for TAP-144-SR].
【期刊】：Hinyokika Kiyo.
【年、卷、期、起止页码】:1990 Nov;36(11):1343-60.
【全文链接】：https://www.ncbi.nlm.nih.gov/pubmed/2126912
【序号】：3
【作者】：Okada H1, Heya T, Ogawa Y, Shimamoto T.
【题名】：One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist
(leuprolide acetate) for treating experimental endometriosis in rats.
【期刊】：J Pharmacol Exp Ther.
【年、卷、期、起止页码】:1988 Feb;244(2):744-50.
【全文链接】：https://www.ncbi.nlm.nih.gov/pubmed/3126294
【序号】：4
【作者】：Taguchi T1, Koyama H, Yayoi K, Wada T, Takatsuka Y, Sonoo H, Morimoto K, Tominaga T, Abe R,
Enomoto K, et al.
【题名】：[Long-term clinical study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal
patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group].
【期刊】：Gan To Kagaku Ryoho.
【年、卷、期、起止页码】:1995 Mar;22(4):495-508.
【全文链接】：https://www.ncbi.nlm.nih.gov/pubmed/7887641